GRBK Q1 2026 Earnings Strong BottomLine Beat Despite Modest Stock Dip Crown Holdings CCK Q1 2026 Earnings EPS Surpasses Expectations with 643 Beat TG Therapeutics Q1 2026 Earnings EPS Disappoints as Stock Declines VSTS Q1 2026 Earnings EPS Surges 89 Above Estimates Stock Gains RLGT Q1 2026 Earnings EPS Surpasses Estimates with 659 Beat Beneficient BENF Slides 144 as Selling Pressure Builds Near Key Resistance Dyne Therapeutics DYN Holds Steady at 1737 as Traders Eye Key Support and Resistance Levels Mineralys Therapeutics MLYS Holds Steady Near Resistance as Volume Remains Muted Copa Holdings CPA Holds Steady Near Support Amid Minimal Volatility IN8bio Q1 2026 Earnings EPS Beat Drives Modest Stock Gain as Development Costs Remain under Control